First-line Helicobacter pylori eradication rates are significantly lower in patients with than those without type 2 diabetes mellitus

References

• Cave DR. How is Helicobacter pylori transmitted? Gastroenterology. 1997;113(6 Suppl):S9–S14.9394753
   PubMed Web of Science ®Google Scholar
• Mentis A, Lehours P, Megraud F. Epidemiology and diagnosis of Helicobacter pylori infection. Helicobacter. 2015;20(Suppl 1):1–7. doi:10.1111/hel.12250
   Web of Science ®Google Scholar
• World Health Organization, International Agency for Research on Cancer (IARC). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 61, Schistosomes, Liver Flukes and Helicobacter Pylori. Lyon: IARC; 1994:177–240.
   Google Scholar
• Graham DY. Helicobacter pylori infection in the pathogenesis of duodenal ulcer and gastric cancer: a model. Gastroenterology. 1997;113:1983–1991.9394739
   PubMed Web of Science ®Google Scholar
• Bin L, Meng L. Helicobacter pylori eradication for preventing gastric cancer. World J Gastroenterol. 2014;20:5660–5665. doi:10.3748/wjg.v20.i19.566024914325
   PubMed Web of Science ®Google Scholar
• Correa P, Piazuelo MB. The gastric precancerous cascade. J Dig Dis. 2012;13:2–9. doi:10.1111/j.1751-2980.2011.00550.x22188910
   PubMed Web of Science ®Google Scholar
• Rugge M, Genta RM, Di Mario F, et al. Gastric cancer as preventable disease. Clin Gastroenterol Hepatol. 2017;15(12):1833–1834. doi:10.1016/j.cgh.2017.05.02328532700
   PubMed Web of Science ®Google Scholar
• Mommersteeg MC, Yu J, Peppelenbosch MP, Fuhler GM. Genetic host factors in Helicobacter pylori-induced carcinogenesis: emerging new paradigms. Biochim Biophys Acta Rev Cancer. 2018;1869(1):42–52. doi:10.1016/j.bbcan.2017.11.00329154808
   PubMed Web of Science ®Google Scholar
• Waluga M, Kukla M, Żorniak M, Bacik A, Kotulski R. From the stomach to other organs: Helicobacter pylori and the liver. World J Hepatol. 2015;7:2136–2146. doi:10.4254/wjh.v7.i18.213626328025
   PubMed Web of Science ®Google Scholar
• Trinchieri G. Cancer and inflammation: an old intuition with rapidly evolving new concepts. Annu Rev Immunol. 2012;30:677–706. doi:10.1146/annurev-immunol-020711-07500822224761
   PubMed Web of Science ®Google Scholar
• Tseng CH. Diabetes, insulin use and Helicobacter pylori eradication: a retrospective cohort study. BMC Gastroenterol. 2012;12:46. doi:10.1186/1471-230X-12-16022571603
   PubMed Web of Science ®Google Scholar
• Vafaeimanesh J, Parham M, Seyyedmajidi M, et al. Helicobacter pylori infection and insulin resistance in diabetic and nondiabetic population. Sci World J. 2014;2014:391250. doi:10.1155/2014/391250
   Google Scholar
• Kayar Y, Pamukcu O, Eroglu H, et al. Relationship between Helicobacter pylori infections in diabetic patients and inflammations, metabolic syndrome, and complications. Int J Chronic Dis. 2015;2015:290128.26464868
   PubMedGoogle Scholar
• Han X, Li Y, Wang J, et al. Helicobacter pylori infection is associated with type 2 diabetes among a middle- and old-age Chinese population. Diabetes Metab Res Rev. 2016;32:95–101. doi:10.1002/dmrr.267726172433
   PubMed Web of Science ®Google Scholar
• Bonfigli AR, Boemi M, Festa R, et al. Randomized, double-blind, placebo-controlled trial to evaluate the effect of Helicobacter pylori eradication on glucose homeostasis in type 2 diabetic patients. Nutr Metab Cardiovasc Dis. 2016;26:893–898. doi:10.1016/j.numecd.2016.06.01227480449
   PubMed Web of Science ®Google Scholar
• Chen Y, Blaser MJ. Association between gastric Helicobacter pylori colonization and glycated hemoglobin levels. J Infect Dis. 2012;205:1195–1202. doi:10.1093/infdis/jis10622427676
   PubMed Web of Science ®Google Scholar
• Vafaeimanesh J, Rajabzadeh R, Ahmadi A, et al. Effect of Helicobacter pylori eradication on glycaemia control in patients with type 2 diabetes mellitus and comparison of two therapeutic regimens. Arab J Gastroenterol. 2013;14:55–58. doi:10.1016/j.ajg.2013.03.00223820501
   PubMed Web of Science ®Google Scholar
• Cho DK, Park SY, Kee WJ, et al. [The trend of eradication rate of Helicobacter pylori infection and clinical factors that affect the eradication of first-line therapy]. Korean J Gastroenterol. 2010;55:368–375. 20100625420571304
   PubMedGoogle Scholar
• Demir M, Gokturk S, Ozturk NA, et al. Bismuth-based first-line therapy for Helicobacter pylori eradication in type 2 diabetes mellitus patients. Digestion. 2010;82:47–53. doi:10.1159/00023602420410684
   PubMed Web of Science ®Google Scholar
• Chuah SK, Hsu PI, Chang KC, et al. Randomized comparison of two on-bismuth-containing second-line rescue therapies for Helicobacter pylori. Helicobacter. 2012;17:216–223. doi:10.1111/j.1523-5378.2012.00937.x22515360
   PubMed Web of Science ®Google Scholar
• Chuah SK, Liang CM, Lee CH, et al. A randomized control trial comparing two levofloxacin-containing second-line therapies for Helicobacter pylori eradication. Medicine (Baltimore). 2016;95:e3586. doi:10.1097/MD.000000000000486427175657
   PubMed Web of Science ®Google Scholar
• Hamrah MS, Hamrah MH, Ishii H, et al. Association between Helicobacter pyloriinfection and cardiovascular risk factors among patients in the Northern part of Afghanistan: a cross-sectional study in Andkhoy City. Asian Pac J Cancer Prev. 2018;19:1035–1039. doi:10.22034/APJCP.2018.19.4.103529693980
   PubMedGoogle Scholar
• Den Hollander WJ, Broer L, Schurmann C, et al. Helicobacter pyloricolonization and obesity – a Mendelian randomization study. Sci Rep. 2017;7(1):14467. doi:10.1038/s41598-017-14106-429089580
   PubMed Web of Science ®Google Scholar
• Xia HHN, Talley NJ, Kam EPY, et al. Helicobacter pylori infection is not associated with diabetes mellitus, nor with upper gastrointestinal symptoms in diabetes mellitus. Am J Gastroenterol. 2001;96:1039–1046. doi:10.1111/j.1572-0241.2001.03604.x11316144
   PubMed Web of Science ®Google Scholar
• Wada Y, Hamamoto Y, Kawasaki Y, et al. The eradication of Helicobacter pyloridoes not affect glycemic control in Japanese subjects with type 2 diabetes. Jpn Clin Med. 2013;4:41–43. doi:10.4137/JCM.S1082823966817
   PubMedGoogle Scholar
• Gasbarrini A, Ojetti V, Pitocco D, et al. Insulin-dependent diabetes mellitus affects eradi cation rate of Helicobacter pylori infection. Eur J Gastroenterol Hepatol. 1999;11:713–716.10445788
   PubMed Web of Science ®Google Scholar
• Wu IT, Chuah SK, Lee CH, et al. Five-year sequential changes in secondary antibiotic resistance of Helicobacter pylori in Taiwan. World J Gastroenterol. 2015;21(37):10669–10674. doi:10.3748/wjg.v21.i37.1066926457027
   PubMed Web of Science ®Google Scholar
• Gasbarrini A, Ojetti V, Pitocco D, et al. Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulin-dependent diabetes mellitus. Scand J Gastroenterol. 2000;35:260–263.10766318
   PubMed Web of Science ®Google Scholar
• Bégué RE, Gómez R, Compton T, Vargas A. Effect of Helicobacter pylori eradication in the glycemia of children with type 1 diabetes: a preliminary study. South Med J. 2002;95:842–845. doi:10.1097/00007611-200295080-0001212190218
   PubMed Web of Science ®Google Scholar
• Sargyn M, Uygur-Bayramicli O, Sargyn H, et al. Type 2 diabetes mellitus affects eradication rate of Helicobacter pylori. World J Gastroenterol. 2003;9:1126–1128.12717872
   PubMed Web of Science ®Google Scholar
• Demir M, Gokturk HS, Ozturk NA, et al. Efficacy of two different Helicobacter pylorieradication regimens in patients with type 2 diabetes and the effect of Helicobacter pylori eradication on dyspeptic symptoms in patients with diabetes: a randomized controlled study. Am J Med Sci. 2009;338:459–464. doi:10.1097/MAJ.0b013e3181b5d3cf19884816
   PubMed Web of Science ®Google Scholar
• Demir M, Gokturk HS, Ozturk NA, et al. Clarithromycin resistance and efficacy of clarithromycin-containing triple eradication therapy for Helicobacter pylori infection in type 2 diabetes mellitus patients. South Med J. 2009;102:1116–1120. doi:10.1097/SMJ.0b013e3181bca53819864973
   PubMed Web of Science ®Google Scholar
• Unger RH, Foster DW. Diabetes mellitus In: Wilson JD, Foster DW, editors. Williams’ Text-Book of Endocrinology. 8 ed. Philadelphia: Saunders; 1992:1255–1333.
   Google Scholar
• Marhoffer W, Stein M, Maeser E, Federlin K. Impairment of polymorphonuclear leukocyte function and metabolic control of diabetes. Diabetes Care. 1992;15:256–260. doi:10.2337/diacare.15.2.2561547682
   PubMed Web of Science ®Google Scholar
• Gwilt PR, Nahas RR, Tracewell WG. The effects of diabetes mellitus on pharmocokinetics and pharmacodynamics in humans. Clin Pharmacokinet. 1991;20:477–490. doi:10.2165/00003088-199120060-000042044331
   PubMed Web of Science ®Google Scholar
• Megraud F. Resistance of Helicobacter pylori to antibiotics. Aliment Pharmacol Ther. 1997;11(Suppl 1):43–53.9146790
   PubMed Web of Science ®Google Scholar
• Jaap AJ, Shore AC, Tooke JE. Relationship of insulin resistance to microvascular dysfunction of subjects with fasting hyperglycaemia. Diabetologia. 1997;40:238–243. doi:10.1007/s0012500506699049487
   PubMed Web of Science ®Google Scholar
• Marietti M, Gasbarrini A, Saracco G, Pellicano R. Helicobacter pylori infection and diabetes mellitus: the 2013 state of art. Panminerva Med. 2013;55:277–281.24088801
   PubMed Web of Science ®Google Scholar
• Liou JM, Chang CY, Chen MJ, et al. The primary resistance of Helicobacter pylori in Taiwan after the national policy to restrict antibiotic consumption and its relation to virulence factors—a nationwide study. PLoS One. 2015;10:e0124199. doi:10.1371/journal.pone.012419925942450
   PubMed Web of Science ®Google Scholar
• Ataseven H, Demir M, Gen R. Effect of sequential treatment as a first-line therapy for Helicobacter pylori eradication in patients with diabetes mellitus. South Med J. 2010;10:988–992. doi:10.1097/SMJ.0b013e3181eea6cc
   Web of Science ®Google Scholar